Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Show more

Location: 1065 East Hillsdale Boulevard, Foster City, CA, 94404, United States | Website: https://www.ternspharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

428M

52 Wk Range

$1.86 - $11.40

Previous Close

$4.87

Open

$4.82

Volume

720,991

Day Range

$4.66 - $4.96

Enterprise Value

-7.259M

Cash

334.3M

Avg Qtr Burn

-17.91M

Insider Ownership

0.28%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Phase 2a

Update

TERN-701 (Allosteric BCR-ABL inhib) Details
Chronic myeloid leukemia (CML)

Phase 1

Data readout

TERN-101 (FXR agonist) Details
Non-alcoholic steatohepatitis

Failed

Discontinued

TERN-201 (VAP-1 inhibitor) Details
Non-alcoholic steatohepatitis

Failed

Discontinued